Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 18, Number 1—January 2012

Dispatch

Emergence of Blastoschizomyces capitatus Yeast Infections, Central Europe

Tanja BirrenbachComments to Author , Sonja Bertschy, Franziska Aebersold, Nicolas J. Mueller, Yvonne Achermann, Konrad Muehlethaler, and Stefan Zimmerli
Author affiliations: University Hospital Bern, Bern, Switzerland (T. Birrenbach, S. Zimmerli); Kantonsspital Luzern, Lucern, Switzerland (S. Bertschy, F. Aebersold); University Hospital Zurich, Zurich, Switzerland (N.J. Mueller, Y. Achermann); University of Bern, Bern (K. Muehlethaler, S. Zimmerli)

Main Article

Table 2

In vitro antifungal susceptibility profile according to microtiter broth dilution for patients with Blastoschizomyces capitatus yeast infections, Switzerland, June 2009–June 2010*

Patient no. MIC, μg/mL
AMB 5-FC FLC ITC VRC POS CAS
1 0.5 0.03 2 0.06 0.016 0.25 4
2 0.5 0.03 8 0.12 0.06 0.25 4
3 0.5 (3)† 0.06 4 0.06 0.06 0.25 8
4 0.5 16 1 0.032 0.032 0.064 4
5 0.5 0.12 16 0.25 0.25 0.5 >16

*AMB, deoxycholate amphotericin B; 5-FC, 5-fluorocytosine; FLC, fluconazole; ITC, itraconazole; VRC, voriconazole; POS, posaconazole; CAS, caspofungin.
†By Etest (bioMérieux, Marcy l’Etoile, France), the isolate had an AMB MIC of 3 μg/mL.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO